Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0

Toru Mukohara; Yeon Hee Park; David Sommerhalder; Kan Yonemori; Erika Hamilton; Sung Bae Kim; Jee Hyun Kim; Hiroji Iwata; Toshinari Yamashita; Rachel M. Layman; Monica Mita; Timothy Clay; Yee Soo Chae; Catherine Oakman; Fengting Yan; Gun Min Kim; Seock Ah Im; Geoffrey J. Lindeman; Hope S. Rugo; Marlon Liyanage; Michelle Saul; Christophe Le Corre; Athanasia Skoura; Li Liu; Meng Li; Patricia M. LoRusso

doi:10.1038/s41591-024-03129-w

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0

Toru Mukohara
, Yeon Hee Park
, David Sommerhalder
, Kan Yonemori
, Erika Hamilton
, Sung Bae Kim
, Jee Hyun Kim
, Hiroji Iwata
, Toshinari Yamashita
, Rachel M. Layman
, Monica Mita
, Timothy Clay
, Yee Soo Chae
, Catherine Oakman
, Fengting Yan
, Gun Min Kim
, Seock Ah Im
, Geoffrey J. Lindeman
, Hope S. Rugo
, Marlon Liyanage

Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M. LoRusso

Department of Internal Medicine

National Cancer Center Japan
NEXT Oncology
Sarah Cannon Research Institute
University of Ulsan
Seoul National University
Nagoya City University
Kanagawa Cancer Center Research Institute
University of Texas MD Anderson Cancer Center
Hoag Family Cancer Institute
Saint John of God Subiaco Hospital
Kyungpook National University
Western Health
Swedish Medical Center
Yonsei University
Walter and Eliza Hall Institute of Medical Research
University of California at San Francisco
Pfizer
Yale University

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024 In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig. 5, “(confirmed)” has been removed from both graph legends, which originally read “Best overall response (confirmed)”. In Extended Data Table 1, the title of Table 1B has been corrected from “PF-07248144 dose and DLT relationship” to “Bayesian Logistic Regression Model: Predicted probability of DLT”. These corrections have been made to the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	2371
Number of pages	1
Journal	Nature Medicine
Volume	30
Issue number	8
DOIs	https://doi.org/10.1038/s41591-024-03129-w
State	Published - Aug 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41591-024-03129-w

Cite this

Mukohara, T., Park, Y. H., Sommerhalder, D., Yonemori, K., Hamilton, E., Kim, S. B., Kim, J. H., Iwata, H., Yamashita, T., Layman, R. M., Mita, M., Clay, T., Chae, Y. S., Oakman, C., Yan, F., Kim, G. M., Im, S. A., Lindeman, G. J., Rugo, H. S., ... LoRusso, P. M. (2024). Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0. Nature Medicine, 30(8), 2371. https://doi.org/10.1038/s41591-024-03129-w

@article{f698bf57f72c449d85c2c8a13ea743f8,

title = "Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024 In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig. 5, “(confirmed)” has been removed from both graph legends, which originally read “Best overall response (confirmed)”. In Extended Data Table 1, the title of Table 1B has been corrected from “PF-07248144 dose and DLT relationship” to “Bayesian Logistic Regression Model: Predicted probability of DLT”. These corrections have been made to the HTML and PDF versions of the article.",

author = "Toru Mukohara and Park, \{Yeon Hee\} and David Sommerhalder and Kan Yonemori and Erika Hamilton and Kim, \{Sung Bae\} and Kim, \{Jee Hyun\} and Hiroji Iwata and Toshinari Yamashita and Layman, \{Rachel M.\} and Monica Mita and Timothy Clay and Chae, \{Yee Soo\} and Catherine Oakman and Fengting Yan and Kim, \{Gun Min\} and Im, \{Seock Ah\} and Lindeman, \{Geoffrey J.\} and Rugo, \{Hope S.\} and Marlon Liyanage and Michelle Saul and \{Le Corre\}, Christophe and Athanasia Skoura and Li Liu and Meng Li and LoRusso, \{Patricia M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = aug,

doi = "10.1038/s41591-024-03129-w",

language = "English",

volume = "30",

pages = "2371",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "8",

}

Mukohara, T, Park, YH, Sommerhalder, D, Yonemori, K, Hamilton, E, Kim, SB, Kim, JH, Iwata, H, Yamashita, T, Layman, RM, Mita, M, Clay, T, Chae, YS, Oakman, C, Yan, F, Kim, GM, Im, SA, Lindeman, GJ, Rugo, HS, Liyanage, M, Saul, M, Le Corre, C, Skoura, A, Liu, L, Li, M & LoRusso, PM 2024, 'Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0', Nature Medicine, vol. 30, no. 8, pp. 2371. https://doi.org/10.1038/s41591-024-03129-w

TY - JOUR

T1 - Author Correction

T2 - Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0

AU - Mukohara, Toru

AU - Park, Yeon Hee

AU - Sommerhalder, David

AU - Yonemori, Kan

AU - Hamilton, Erika

AU - Kim, Sung Bae

AU - Kim, Jee Hyun

AU - Iwata, Hiroji

AU - Yamashita, Toshinari

AU - Layman, Rachel M.

AU - Mita, Monica

AU - Clay, Timothy

AU - Chae, Yee Soo

AU - Oakman, Catherine

AU - Yan, Fengting

AU - Kim, Gun Min

AU - Im, Seock Ah

AU - Lindeman, Geoffrey J.

AU - Rugo, Hope S.

AU - Liyanage, Marlon

AU - Saul, Michelle

AU - Le Corre, Christophe

AU - Skoura, Athanasia

AU - Liu, Li

AU - Li, Meng

AU - LoRusso, Patricia M.

PY - 2024/8

Y1 - 2024/8

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024 In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig. 5, “(confirmed)” has been removed from both graph legends, which originally read “Best overall response (confirmed)”. In Extended Data Table 1, the title of Table 1B has been corrected from “PF-07248144 dose and DLT relationship” to “Bayesian Logistic Regression Model: Predicted probability of DLT”. These corrections have been made to the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024 In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig. 5, “(confirmed)” has been removed from both graph legends, which originally read “Best overall response (confirmed)”. In Extended Data Table 1, the title of Table 1B has been corrected from “PF-07248144 dose and DLT relationship” to “Bayesian Logistic Regression Model: Predicted probability of DLT”. These corrections have been made to the HTML and PDF versions of the article.

UR - https://www.scopus.com/pages/publications/85196708245

U2 - 10.1038/s41591-024-03129-w

DO - 10.1038/s41591-024-03129-w

M3 - Comment/debate

C2 - 38914862

AN - SCOPUS:85196708245

SN - 1078-8956

VL - 30

SP - 2371

JO - Nature Medicine

JF - Nature Medicine

IS - 8

ER -

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial(Nature Medicine, 10.1038/s41591-024-03060-0

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this